July 5, 2017
Emergency naloxone treatment distributed to tens of thousands of first responders since Health Canada interim order a year ago...
June 20, 2017
Adapt Pharma Acknowledges the U.S. Drug Enforcement Administration (DEA) New Guidance to First Responders on the Hazards of Exposure to Fentanyl...
June 12, 2017
Adapt Pharma Presents Human Factors Study Data at 2017 International Conference on Opioids....
June 6, 2017
Survey Data Published on Community Use of NARCAN® (naloxone HCI) Nasal Spray 4 mg to Help Reverse Opioid-Related Overdose - Current Medical Research and Opinion Journal...
June 6, 2017
Adapt Pharma Clarifies Confusion Between NARCAN™ Nasal Spray and Injectable Naloxone Emergency Opioid Treatments...
April 24, 2017
Emergency opioid treatment NARCAN™ Nasal Spray added to NIHB Program in Canada Registered First Nations and recognized Inuit now have access to additional naloxone treatment...
April 10, 2017
Adapt Pharma announced today that it will donate 20,000 cartons (40,000 doses) of NARCAN® (naloxone hydrochloride) Nasal Spray 4mg to colleges and universities throughout the United States....
March 16, 2017
Adapt Pharma (www.AdaptPharma.com) today presented results of a survey conducted with Police and Community Organizations describing real-world experiences and outcomes with the FDA-approved 4mg...
February 28, 2017
NARCAN® Nasal Spray is the only FDA-approved naloxone nasal spray indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous syste...
February 21, 2017
Adapt Pharma Limited (Adapt Pharma) today announced that a marketing application for Naloxone Hydrochloride (HCl) Nasal Spray for the treatment of opioid overdose has been filed in Europe....
January 25, 2017
Today, the U.S. Food and Drug Administration (FDA) approved NARCAN® Nasal Spray as a 2mg formulation for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and...
December 1, 2016
Ohio Attorney General Mike DeWine announced an agreement on Friday, 11/25/16 with Adapt Pharma to provide NARCAN® (naloxone HCl) Nasal Spray 4mg at a discounted rate to state police, first responders,...
November 22, 2016
FDA Suggests that Before Taking Opioids Consumers Ask Their Physician About a Naloxone Prescription ...
November 4, 2016
Reported shortage of non-FDA approved improvised nasal naloxone kits....
October 6, 2016
FDA Joint Meeting Endorses Commitment to Higher Doses and Broader Access for Naloxone to Help in Fight Against Opioid Overdose ...
October 5, 2016
Adapt Pharma Announces NARCAN® coverage with California’s Medi-Cal Program. Agreement Results in Restriction-Free, $0 Copay Access to NARCAN® Nasal Spray for Millions of Californians...
October 3, 2016
Existing Interim Order Allows Continuing Access in Canada to the US FDA-approved Narcan® Nasal Spray Pending Launch of the Health Canada Approved Version...
September 20, 2016
Newly Published Study Finds NARCAN® Nasal Spray’s Concentrated Formulation Rapidly Delivers an Effective Naloxone Dose and is Readily Usable by the General Public...
July 12, 2016
Adapt Pharma to Launch Program to Raise Awareness, Expand Access and Facilitate Product Experience of NARCAN® (Naloxone HCl) Nasal Spray - a new Treatment for Opioid Overdose...
July 6, 2016
Earlier today, Health Canada announced it will establish temporary access to the only U.S. Food and Drug Administration (FDA) approved, intranasal version of naloxone, NARCAN® Nasal Spray, the medicat...
May 2, 2016
Adapt Pharma submits NDS to Health Canada for Naloxone Nasal Spray...
April 28, 2016
Today, high schools across the country can join their communities in the battle against the opioid epidemic...
April 14, 2016
Introducing the NARCAN® Now App, a smartphone application providing opioid overdose recognition education and treatment instructions...
April 11, 2016
Adapt Pharma Names Mike Kelly President of U.S. Operations. Contributing Over 25 Years of Pharmaceutical Expertise to Adapt Executive Team...
February 25, 2016
Adapt Pharma, Limited (www.adaptpharma.com) today announced the United States (U.S.) commercial availability of NARCAN® (Naloxone Hydrochloride) Nasal Spray...
January 25, 2016
Adapt Pharma to offer all U.S. high schools a free NARCAN® Nasal Spray...
January 14, 2016
Adapt Pharma facilitates NARCAN® (naloxone hydrochloride) Nasal Spray access to state and local public entities...
November 19, 2015
NARCAN® (naloxone hydrochloride) Nasal Spray approved by U.S. food and drug administration...
September 24, 2015
FDA accepts for review Adapt Pharma’s NARCAN® (naloxone hydrochloride) Nasal Spray NDA...
July 27, 2015
Adapt Pharma submits NDA to FDA for NARCAN® (Naloxone) Nasal Spray...
July 2, 2015
Adapt Pharma acquires NARCAN NDA and obtains license to the NARCAN® trademark...
June 3, 2015
Adapt Pharma Commences Rolling NDA Submission to the FDA for Intranasal Naloxone...
April 22, 2015
Adapt Pharma Announces Successful Completion of Intranasal Naloxone Study...
February 17, 2015
Adapt Pharma Announces Fast Track Designation From FDA for Naloxone Nasal Spray...
January 5, 2015
Adapt Pharma and Profector Life Sciences Enter a Development and Investment Collaboration...
December 16, 2014
Adapt Pharma Announces License Agreement for Naloxone Nasal Spray With Lightlake Therapeutics Inc....
May 2, 2014
Adapt Pharma Completes $95 Million Equity Financing U.S. Focused Specialty Pharmaceutical Company...